Therapeutics Pipeline
Program: Indication | Development | Pre-IND | Phase 1 | Phase 2 |
---|---|---|---|---|
AS1411: Acute Myeloid Leukemia (AML) | ![]() |
![]() |
![]() |
![]() |
AS1411: Renal Cell (Kidney) | ![]() |
![]() |
![]() |
![]() |
AS1411: Pancreatic | ![]() |
![]() |
![]() |
![]() |
ALAN: Acute Myeloid Leukemia (AML) | ![]() |
![]() |
![]() |
![]() |
ALAN: Neuroblastoma | ![]() |
![]() |
![]() |
![]() |
ALAN: Pancreatic | ![]() |
![]() |
![]() |
![]() |
ALAN-RE: Radiation Enhancement-Breast (Triple Negative) | ![]() |
![]() |
![]() |
![]() |
ALAN-CE: Contrast Enhancement-Solid Tumors | ![]() |
![]() |
![]() |
![]() |
STARS: All types | ![]() |
![]() |
![]() |
![]() |
RAS-F: Pancreatic | ![]() |
![]() |
![]() |
![]() |
RAS-F: Lung | ![]() |
![]() |
![]() |
![]() |
RAS-F: Colorectal | ![]() |
![]() |
![]() |
![]() |